Cervical cancer screening guidelines updated: Here’s what American Cancer Society recommends now

Cervical cancer screening guidelines updated: Here’s what American Cancer Society recommends now

With approximately 660,000 new cases and 350,000 deaths in 2022, cervical cancer remains one of the deadliest diseases women encounter worldwide, the fourth most common cancer in women. The vast majority of these cases — around 94% — occur in low- and middle-income countries, which indicates significant global inequities in access to vaccination, cancer screening, and treatment.

Talking about cervical cancer screening, this year, the world of cervical cancer screening has taken a major leap forward, as the American Cancer Society (ACS) has updated its cervical cancer screening guidance to reflect new science and more options for people with a cervix.

On December 4, ACS announced a new set of guidelines to make cervical cancer screening easier, more accessible, and more effective. In simple terms, the update means that more people — even those unable or uncomfortable visiting a clinic — can get tested; and there is now clearer advice on when screening can safely stop.

The headline changes? As per the new guidelines, cervical cancer screening should start at age 25 and continue until about 65, and as per the ACS, the preferred test is the HPV test alone every five years. Another crucial bit: the ACS now recognizes self-collected vaginal samples for HPV testing as a valid option in some settings — a move meant to reach people who face barriers to clinic-based screening or who find pelvic exams stressful. If an HPV-only test isn’t available, the ACS still supports either a Pap (cytology) every three years or HPV/Pap co-testing every five years.

The changes come at a time when even modern medical systems are striving to reduce barriers to early detection and improve health equity. Read on to know a detailed breakdown of what’s new, what remains the same, and how these changes could reshape cervical cancer prevention.

First and foremost, self-collection of vaginal samples for HPV testing is now acceptable. For the first time, ACS allows individuals to collect their own vaginal specimen for a primary Human papillomavirus (HPV) test — either in a clinic or potentially at home — as part of routine screening. While clinician-collected cervical samples remain preferred, self-collection offers a major step in increasing accessibility.

Apart from that, there’s also clearer guidance for when to stop screening (“exit criteria”). The updated guidelines provide more specific rules for when people can safely discontinue screening, reducing ambiguity for both individuals and healthcare providers.

According to ACS, these changes are meant to improve compliance — especially among people who may face barriers to traditional screening (lack of access, discomfort with pelvic exams, geographic constraints) — while maintaining or improving the effectiveness of early cancer detection.

The new recommendations from ACS apply to people with a cervix who are at “average risk.”

As per the guidelines, cervical cancer screening should begin at no later than the age of 25. ACS notes that cervical cancer is rare before age 25, and the risks and harms of earlier screening outweigh the benefits. Along with that, the age range for regular screening is 25-65, i.e., individuals aged 25 to 65 should be screened.

What are the recommended methods and intervals?

• Primary HPV test (preferred) every 5 years.
• In case primary HPV testing is unavailable, then either go for an HPV and Pap (cytology) co-test every 5 years, or a Pap test alone every 3 years.

With the new guidance, if you choose self-collected vaginal HPV testing and the result is negative, the recommendation is to repeat screening in 3 years (instead of 5). However, for the classic clinician-collected test, every 5 years remains the standard.

These screening intervals balance effectiveness (detecting precancer or cancer early) against potential harms (over-testing, unnecessary follow-ups, anxiety). ACS’s modeling suggests that primary HPV screening starting at 25 could prevent more cancers and deaths than the older Pap-based schedule, while overall reducing the number of tests needed over a lifetime.

The updated guidelines also clarify when screening may be safely stopped or isn’t needed.

For those at average risk, they can stop screening at age 65 if all prior screening results over the last 10 years have been normal and there has been no history of serious precancerous changes (e.g., no diagnosis of high-grade lesions such as CIN2 or worse in the past 25 years). Furthermore, there’s no need to screen individuals who have had a hysterectomy with removal of the cervix, unless they had prior serious precancerous lesions or cervical cancer. Additionally, individuals younger than age 25 are also excluded from routine screening under these guidelines.

As ACS notes, once screening ends per these criteria, it generally should not be restarted, unless new risk factors appear.

Firstly, it’s a meaningful step forward toward expanded access and better compliance. Allowing self-collection of samples for HPV testing — possibly even outside a traditional clinic — is a breakthrough. It can help reach people who live in remote or underserved areas, have mobility or transport issues, feel uncomfortable with pelvic exams, or simply avoid screening due to stigma or privacy concerns. This flexibility can help close screening gaps and reach populations who previously faced barriers. As ACS itself emphasized, the move is expected to improve screening compliance and cut cervical cancer risk.

Next comes the streamlined screening schedule, which enables fewer tests, with less of a burden. Shifting to primary HPV testing every 5 years reduces the number of lifetime tests compared to older cytology-based schedules — yet, according to modeling, it may prevent more cancers and deaths. That’s a win for all — patients, providers, and public health systems.

Then there’s a set of clear exit rules to build confidence and reduce overtesting, as the updated guidance on when screening can safely stop gives clarity. With the updated guidelines, people and clinicians can make informed decisions, avoid unnecessary tests, and focus resources where they matter most.

With the updated guidelines, self-collected HPV testing is not meant to replace clinical care entirely. It’s an evidence-backed option to reach under-screened groups, increase convenience, and reduce barriers like lack of transportation, childcare, or embarrassment. Regulators and health systems are moving toward approving and offering validated self-collection kits, while private companies and pilot programs are already active. However, clinician-collected samples remain the standard when feasible, and positive results require in-person follow-up.

First, if you have a cervix and are 25–65 years old, talk to your doctor about getting an HPV test. Ask if self-collection is an option. If you have resisted screening because of discomfort or access issues, self-collection might make a big difference.

Then comes the chapter of keeping track of your test results and screening history — this helps determine when screening can be safely stopped (e.g., around age 65).

Additionally, always keep the vaccination in mind. HPV vaccination prevents the infections that cause most cervical cancers. It’s complementary to, not a replacement for, screening.

However, it’s important to remember that even if you got vaccinated against HPV, the screening guideline still applies — the vaccine doesn’t replace screening.